The landmark DCCT and UKPDS studies clearly showed that tight blood glucose
control greatly improves long-term outcomes for both type 1 and type 2 dia
betics respectively. Some of the new approaches and concepts by which this
may be achieved are described and discussed, including novel insulin analog
ues and delivery means, and the molecular targets being pursued to combat i
nsulin resistance, P-cell deficiency, hepatic glucose overproduction and ob
esity/dyslipidaemia.